Progenitor cells from patients with advanced phase chronic myeloid leukaemia respond to STI571 in vitro and in vivo

Leukemia Research

Volumn 25, Issue 11, 2001, Pages 997-1002

  Marley, Stephen B ^a   Davidson, R John ^a   Lewis, John L ^a   Nguyen, Dao X ^a   Eades, Ann ^a   Parker, Sally ^a   Goldman, John M ^a   Gordon, Myrtle Y ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Chronic myeloid leukaemia; Interferon alpha; Progenitors; STI571; Therapy

Indexed keywords

ALPHA INTERFERON; IMATINIB;

ARTICLE; CELL COUNT; CELL DIVISION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COLONY FORMING UNIT GM; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOGENETICS; DISEASE SEVERITY; FEMALE; HEMATOPOIESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; PRIORITY JOURNAL; STEM CELL;

ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CASE-CONTROL STUDIES; CELL DIVISION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; MYELOID PROGENITOR CELLS; PHILADELPHIA CHROMOSOME; PIPERAZINES; PYRIMIDINES; TUMOR STEM CELLS;

EID: 0034796301     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(01)00066-2     Document Type: Article

References (17)

1. Cellular and molecular mechanisms in chronic myeloid leukaemia: Biology and treatment
2. Cell biology of CML cells
3. The influence of target protein half-life on the effectiveness of antisense oligonucleotide analog-mediated biologic responses
4. Investigating and improving the specificity of ribozymes directed against the bcr-abl translocation
5. Clinical efficacy and safety of an ABL specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia
6. Lessons learnt from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
7. Leukemia drug heralds molecularly targeted era
8. The nuclear tyrosine kinase c-Abl negatively regulates cell growth
9. The tyrosine kinase inhibitor STI571, like interferon-α, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia
10. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
11. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
12. In vivo eradication of human BCR/ABL+ leukemic cells with an ABL kinase inhibitor
13. Treatment with interferon-α preferentially reduces the capacity for amplificatiion of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM
14. Natural history and staging of chronic myelogenous leukaemia
15. The MD Anderson experience with interferon-α therapy in chronic myelogenous leukaemia
16. Mechanism(s) of interferon inhibitory activity in blood from patients with AIDS and patients with lupus erythematosus with vasculitis